Sierra J, Mareque M, Montesinos P, Guinea JM, Font P, Oyaguez I, Brockbank J, Candini D, Llinares J, Soto J, de la Fuente A. Cost-effectiveness of gemtuzumab ozogamicin in combination with standard of care chemotherapy for first-line treatment of patients with CD33-positive acute myeloid leukemia in Spain. Poster presented at the 2020 Virtual European Hematology Association; June 2020.
Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4